Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany.
Institute of Nuclear Medicine, Helios Kliniken, Schwerin, Germany.
Cancer Immunol Immunother. 2019 Jun;68(6):907-915. doi: 10.1007/s00262-019-02323-x. Epub 2019 Mar 15.
In patients with non-resectable hepatic malignancies selective internal radiotherapy (SIRT) with yttrium-90 is an effective therapy. However, previous data indicate that SIRT leads to impaired immune function. The aim of the current study was to determine the extent of DNA lesions in peripheral blood mononuclear cells of SIRT patients and to correlate these lesions with cellular immune responses. In ten patients γH2AX and 53BP1 foci were determined. These foci are markers of DNA double-strand breaks (DSBs) and occur consecutively. In parallel, lymphocyte proliferation was assessed after stimulation with the T cell mitogen phytohemagglutinin. Analyses of vital cells were performed prior to and 1 h and 1 week after SIRT. 1 h and 1 week after SIRT numbers of γH2AX and of 53BP1 foci were more than threefold larger than before (p < 0.01). Already at baseline, foci were more abundant than published in healthy controls. Lymphocyte proliferation at baseline was below the normal range and further decreased after SIRT. Prior to therapy, there was an inverse correlation between lymphocyte proliferation and the quotient 53BP1/γH2AX; which could be considered as a measure of the course of DNA DSB repair (r = - 0.94, p < 0.0001). Proliferative responses were inversely correlated with 53BP1 foci prior to therapy and γH2AX and 53BP1 foci 1 h after therapy (r < - 0.65, p < 0.05). In conclusion, DNA foci in SIRT patients were correlated with impaired in vitro immune function. Unrepaired DNA DSBs or cell cycle arrest due to repair may cause this impairment.
在无法切除的肝恶性肿瘤患者中,钇-90 选择性内放射治疗(SIRT)是一种有效的治疗方法。然而,先前的数据表明 SIRT 会导致免疫功能受损。本研究的目的是确定 SIRT 患者外周血单个核细胞中的 DNA 损伤程度,并将这些损伤与细胞免疫反应相关联。在 10 名患者中,测定了γH2AX 和 53BP1 焦点。这些焦点是 DNA 双链断裂(DSB)的标志物,并且连续出现。同时,在用植物血凝素 T 细胞有丝分裂原刺激后,评估淋巴细胞增殖。在 SIRT 之前和之后 1 小时和 1 周,对活细胞进行分析。SIRT 后 1 小时和 1 周,γH2AX 和 53BP1 焦点的数量比之前增加了三倍以上(p<0.01)。基线时,焦点的数量就已经比已发表的健康对照组更为丰富。基线时淋巴细胞增殖低于正常范围,SIRT 后进一步下降。在治疗前,淋巴细胞增殖与 53BP1/γH2AX 商呈负相关;这可以被认为是 DNA DSB 修复过程的一个衡量标准(r=-0.94,p<0.0001)。治疗前,增殖反应与 53BP1 焦点呈负相关,与治疗后 1 小时的γH2AX 和 53BP1 焦点呈负相关(r<0.65,p<0.05)。总之,SIRT 患者的 DNA 焦点与体外免疫功能受损相关。未修复的 DNA DSB 或由于修复而导致的细胞周期停滞可能导致这种损伤。